Phase 2 N=176 Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients
Trichuris Infection · Helminthiasis
Primary: Cure Rate — 1; 31; 6; 40 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=356,912 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Helminthiasis · Filariasis
Primary: Comparison of Arms - Benin — 322; 748; 11; 11 Participants
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 3 N=295 A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
Helminth Infections
Primary: Cure Rate for Ascaris Lumbricoides at the End of Double-blind Treatment Period — 11.1; 83.7 percentage of participants — p=< 0.001
Phase 2 N=12 Desensitising Celiac Disease Patients With the Human Hookworm
Celiac Disease
Primary: Duodenal Villus Height:Crypt Depth — 2.73; 2.73 Ratio — p=0.693
Phase 2 N=39 Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
Hookworm Infections
Primary: Detectable Hookworm Infection — 0; 0; 0; 0 Participants
N/A N=87 Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
Hookworm Infection
Primary: Size of Wheal Diameter at Site of Skin Test Application, Measured 15 Minutes After Injection — 3.5 cm
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
Phase 2 N=700 Albendazole Dose Finding and Pharmacokinetics in Children and Adults
Trichuriasis · Hookworm Infections
Primary: Cure Rate Against T. Trichiura and Hookworm Infections — 4; 2; 4; 5 Participants
Phase 3 N=255 Efficacy and Safety of MOX/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura — 15.3; 13.4 percentage of participants (%)
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
Phase 4 N=186 Efficacy and Safety of a Multi-dose Regimen of Mebendazole Against Hookworm in Children
Hookworm
Primary: Cure Rate (CR) of Mebendazole Against Hookworm — 13; 97.9 percentage of participants cured
Phase 3 N=214 Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections
Necator Americanus Infection
Primary: Cure Rate — 16.3; 28.3; 18.8 percentage of participants
Early Phase 1 N=12 Ivermectin and Human Immunity
Ivermectin
Primary: The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded. — 0; 0; 0; 0 Cytokines changed from t=0
N/A N=17,108 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Lymphatic Filariasis · Soil Transmitted Helminth Infections
Primary: Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood — 54; 36; 146; 46 Participants
Phase 3 N=536 Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Egg Reduction Rate Against T. Trichiura — 96.8; 99.0; 86.2; 94.2 Percent change
Phase 4 N=41 Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Loiasis
Primary: Cross-reactive Antigenemia — 12 Participants
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Phase 3 N=224 Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC
Trichuriasis · Ascariasis · Hookworm Infections
Primary: Cure Rate (CR) Against T. Trichiura — 69.4; 16.2; 11.8 percentage of participants cured (%)
N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
Phase 2 N=370 S. Japonicum and Pregnancy Outcomes
Schistosomiasis
Primary: Mean Newborn Birth Weight — 2.85; 2.85 kilograms — p=0.988
Phase 2 N=354 Praziquantel in Children Under Age 4
Schistosomiasis · Schistosomiasis Mansoni · Schistosoma Japonicum Infection
Primary: Treatment Efficacy — 96; 98; 96; 98 percentage change
Phase 4 N=12 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Loiasis
Primary: The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment. — 196; 165 percentage of baseline — p=0.68
Phase 1 N=60 Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
Hookworm Disease · Hookworm Infection
Primary: Vaccine-Related Adverse Events — 8; 8; 8; 8 Participants
N/A N=4 Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova
Ulcerative Colitis
Primary: Change From Baseline of Mucus Production at 12 Weeks and 24 Weeks as Assessed by Histopathology
Phase 2 N=8 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Loiasis
Primary: Peak Eosinophil Count Post-treatment — 61; 245.6 percent of baseline eosinophil count — p=0.028
Phase 3 N=223 Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Observed Cure Rate Against Strongyloides Stercoralis — 73.3; 89.7; 84.4; 82.8 percentage of participants
Phase 2 N=73 Niclosamide for Mild to Moderate COVID-19
COVID-19
Primary: Time to Respiratory Viral Clearance — 3.39; 3.44 Days
N/A N=12 Development of a Skin Test for the Na-ASP-2 Hookworm Antigen
Hookworm Infection · Allergy
Primary: 100 Mcg/ml Na-ASP-2 Prick-puncture Skin Test — 0 Units on a scale
Phase 1 N=24 Safety and Immunogenicity Study of Na-GST-1 With or Without CpG
Hookworm Infection · Hookworm Disease
Primary: Vaccine-related Adverse Events — 1; 3; 0; 3 Participants